Description
Cagrilintide is a long-acting, acylated human amylin analogue in clinical development for obesity and type 2 diabetes, often investigated in combination with semaglutide (CagriSema). It acts as a dual amylin and calcitonin receptor agonist, reducing body weight and appetite by acting on brain receptors.
Key Aspects of Cagrilintide:
-
- Mechanism: As an amylin analogue, it enhances satiety (feeling full) and delays gastric emptying.
- Weight Loss: In trials, a 2.4 mg dose of cagrilintide alone showed significant, dose-dependent weight reductions.
- Administration: It is administered via subcutaneous injection.
Cagrilintide is designed to provide greater weight loss when used in combination with other therapies due to its complementary mechanism, which specifically targets appetite regulation
Reviews
There are no reviews yet.